Literature DB >> 25223827

Chronic Statin Use and Long-Term Rates of Sepsis: A Population-Based Cohort Study.

Henry E Wang1, Russell Griffin2, Nathan I Shapiro3, George Howard4, Monika M Safford5.   

Abstract

PURPOSE: "Statins" have immunomodulatory and anti-inflammatory effects and may attenuate the risk of infections. We sought to determine the association between chronic statin use and long-term rates of sepsis events.
MATERIALS AND METHODS: We used data from 30 183 adult (≥45 years old) community-dwelling participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. The primary exposure was statin use. The primary outcome was hospitalization or emergency department treatment for sepsis. Using Cox proportional hazards models, we determined associations between statin use and first sepsis events, adjusting for patients demographics, health behaviors, chronic medical conditions, degree of medication adherence, baseline high-sensitivity C-reactive protein (hsCRP), and propensity for statin use.
RESULTS: Approximately one-third of participants reported statin use (n = 9475, 31.4%). During the 10-year follow-up period from 2003 to 2012, there were 1500 incident sepsis events. Statin use was not associated with rates of sepsis after multivariable adjustment for demographics, health behaviors, chronic medical conditions, medication adherence, abnormal hsCRP, and propensity for statin use, hazard ratio 0.93 (95% confidence interval: 0.81-1.06). Statin use was not similarly associated with rates of sepsis when stratified by propensity for statin use or medication adherence.
CONCLUSION: In the REGARDS cohort, statin use at baseline was not associated with rates of future sepsis events.
© The Author(s) 2014.

Entities:  

Keywords:  epidemiology; infections; sepsis; statins

Mesh:

Substances:

Year:  2014        PMID: 25223827      PMCID: PMC5038131          DOI: 10.1177/0885066614550280

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  50 in total

1.  Assessment and control for confounding by indication in observational studies.

Authors:  B M Psaty; T D Koepsell; D Lin; N S Weiss; D S Siscovick; F R Rosendaal; M Pahor; C D Furberg
Journal:  J Am Geriatr Soc       Date:  1999-06       Impact factor: 5.562

2.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

3.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

4.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

5.  Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule.

Authors:  Nathan I Shapiro; Richard E Wolfe; Richard B Moore; Eric Smith; Elizabeth Burdick; David W Bates
Journal:  Crit Care Med       Date:  2003-03       Impact factor: 7.598

6.  Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome.

Authors:  Hendrik Schmidt; Ralf Hennen; Alexander Keller; Martin Russ; Ursula Müller-Werdan; Karl Werdan; Michael Buerke
Journal:  Intensive Care Med       Date:  2006-06-21       Impact factor: 17.440

7.  Prior statin use is not associated with improved outcome in emergency patients admitted with infection: a prospective observational study.

Authors:  Julian M Williams; Jaimi H Greenslade; Kevin Chu; Anthony F T Brown; David Paterson; Jeffrey Lipman
Journal:  Acad Emerg Med       Date:  2011-02       Impact factor: 3.451

8.  HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.

Authors:  Joel D Mermis; Steven Q Simpson
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

9.  Statin therapy is associated with decreased mortality in patients with infection.

Authors:  Michael W Donnino; Michael N Cocchi; Michael Howell; Peter Clardy; Daniel Talmor; Lauren Cataldo; Maureen Chase; Adel Al-Marshad; Long Ngo; Nathan I Shapiro
Journal:  Acad Emerg Med       Date:  2009-03       Impact factor: 3.451

10.  Statin use and mortality within 180 days after bacteremia: a population-based cohort study.

Authors:  Reimar W Thomsen; Heidi H Hundborg; Søren P Johnsen; Lars Pedersen; Henrik T Sørensen; Henrik C Schønheyder; Hans-Henrik Lervang
Journal:  Crit Care Med       Date:  2006-04       Impact factor: 7.598

View more
  5 in total

1.  Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort.

Authors:  Ninad S Chaudhary; John P Donnelly; Justin X Moore; John W Baddley; Monika M Safford; Henry E Wang
Journal:  Crit Care       Date:  2017-07-13       Impact factor: 9.097

2.  Effects of simvastatin on the expression of inducible NOS in acute lung injury in septic rats.

Authors:  Wei-Chao Li; Zi-Jun Zou; Ming-Gen Zhou; Liang Chen; Lin Zhou; Yu-Kai Zheng; Zhi-Jie He
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Mediating Effects of Frailty Indicators on the Risk of Sepsis After Cancer.

Authors:  Justin Xavier Moore; Tomi Akinyemiju; Alfred Bartolucci; Henry E Wang; John Waterbor; Russell Griffin
Journal:  J Intensive Care Med       Date:  2018-06-03       Impact factor: 3.510

4.  Cholesterol levels and long-term rates of community-acquired sepsis.

Authors:  Faheem W Guirgis; John P Donnelly; Sunita Dodani; George Howard; Monika M Safford; Emily B Levitan; Henry E Wang
Journal:  Crit Care       Date:  2016-12-23       Impact factor: 9.097

Review 5.  Community-onset sepsis and its public health burden: a systematic review.

Authors:  Alexander Tsertsvadze; Pam Royle; Farah Seedat; Jennifer Cooper; Rebecca Crosby; Noel McCarthy
Journal:  Syst Rev       Date:  2016-05-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.